Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

alnuctamab

A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ALNUC
anti-BCMA/CD3 bispecific antibody CC-93269
BCMA x CD3 T cell-engaging antibody CC-93269
BCMA/CD3 T-cell bi-specific antibody CC-93269
BCMA/CD3-directed bispecific T-cell engager antibody CC-93269
BCMAxCD3 BiTE antibody CC-93269
BCMAxCD3 TCB CC-93269
bi-specific antibody CC-93269
Code name:BMS 986349
BMS-986349
BMS986349
CC 93269
CC-93269
CC93269
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search